ABSCI CORP (ABSI) Stock Price, Forecast & Analysis
USA - NASDAQ:ABSI - US00091E1091 - Common Stock
ABSI Key Statistics, Chart & Performance
The current stock price of ABSI is 3.4 USD. In the past month the price decreased by -32%. In the past year, price increased by 19.72%.
ABSI Latest News, Press Relases and Analysis
ABSI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.68 | 412.01B | ||
| AMGN | AMGEN INC | 15.38 | 181.04B | ||
| GILD | GILEAD SCIENCES INC | 15.07 | 153.12B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.01 | 111.32B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.15 | 72.26B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 887.73 | 59.35B | ||
| INSM | INSMED INC | N/A | 41.09B | ||
| NTRA | NATERA INC | N/A | 28.75B | ||
| BIIB | BIOGEN INC | 9.65 | 23.67B | ||
| INCY | INCYTE CORP | 16.86 | 21.14B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.49 | 20.88B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 35.13 | 14.56B |
Related stock screener links
About ABSI
Company Profile
Absci Corp. is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. The company is headquartered in Vancouver Washington, Washington and currently employs 156 full-time employees. The company went IPO on 2021-07-22. Its Integrated Drug Creation platform combines artificial intelligence (AI) models with a synthetic biology data engine, enabling the design of therapeutics that address challenging therapeutic targets. Its approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Alongside collaborations with pharmaceutical, biotech, tech, and academic companies, the Company is advancing its own pipeline of AI- designed therapeutics. These include ABS-101, an antibody to treat inflammatory bowel disease (IBD), as well as other indications, and ABS-201, for hair regrowth with the potential to redefine treatment possibilities for androgenetic alopecia, commonly known as male and female pattern baldness. The company has four wholly owned, internally developed programs focusing on cytokine biology. Its other pipeline programs include ABS-301 and ABS-501.
Company Info
ABSCI CORP
18105 Se Mill Plain Blvd
Vancouver Washington WASHINGTON US
CEO: Sean McClain
Employees: 156
Phone: 13609491041
ABSCI CORP / ABSI FAQ
What does ABSCI CORP do?
Absci Corp. is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. The company is headquartered in Vancouver Washington, Washington and currently employs 156 full-time employees. The company went IPO on 2021-07-22. Its Integrated Drug Creation platform combines artificial intelligence (AI) models with a synthetic biology data engine, enabling the design of therapeutics that address challenging therapeutic targets. Its approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Alongside collaborations with pharmaceutical, biotech, tech, and academic companies, the Company is advancing its own pipeline of AI- designed therapeutics. These include ABS-101, an antibody to treat inflammatory bowel disease (IBD), as well as other indications, and ABS-201, for hair regrowth with the potential to redefine treatment possibilities for androgenetic alopecia, commonly known as male and female pattern baldness. The company has four wholly owned, internally developed programs focusing on cytokine biology. Its other pipeline programs include ABS-301 and ABS-501.
What is the current price of ABSI stock?
The current stock price of ABSI is 3.4 USD. The price decreased by -1.45% in the last trading session.
Does ABSCI CORP pay dividends?
ABSI does not pay a dividend.
What is the ChartMill rating of ABSCI CORP stock?
ABSI has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the valuation of ABSCI CORP (ABSI) based on its PE ratio?
ABSCI CORP (ABSI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.9).
What is ABSCI CORP worth?
ABSCI CORP (ABSI) has a market capitalization of 508.37M USD. This makes ABSI a Small Cap stock.
Can you provide the upcoming earnings date for ABSCI CORP?
ABSCI CORP (ABSI) will report earnings on 2026-03-16, after the market close.
ABSI Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to ABSI. When comparing the yearly performance of all stocks, ABSI is one of the better performing stocks in the market, outperforming 80.47% of all stocks.
ABSI Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ABSI. While ABSI seems to be doing ok healthwise, there are quite some concerns on its profitability.
ABSI Financial Highlights
Over the last trailing twelve months ABSI reported a non-GAAP Earnings per Share(EPS) of -0.9. The EPS increased by 3.64% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -53.98% | ||
| ROE | -65.35% | ||
| Debt/Equity | 0 |
ABSI Forecast & Estimates
15 analysts have analysed ABSI and the average price target is 7.97 USD. This implies a price increase of 134.45% is expected in the next year compared to the current price of 3.4.
For the next year, analysts expect an EPS growth of 5.49% and a revenue growth 2.95% for ABSI